The Pharma Letter |
Biologic May Tame Severe Asthma
MedPage Today A. A. Take Posttest. SAN DIEGO — Lebrikizumab, a novel monoclonal antibody against the inflammatory cytokine IL-13, might have reduced exacerbations in severe asthma in a randomized trial, although manufacturing problems undermined any conclusions. Roche drug cuts asthma attacks, improves lung function -study Roche scores upbeat data for a personalized asthma drug with blockbuster hopes AAAAI 2014: Roche's lebrikizumab shows reduction of asthma attack rates |
View full post on asthma – Google News